Clinical trials: Cancer, Bladder
Bladder Cancer, Gastric Cancer
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
A phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 in combination with pembrolizumab in subjects with solid tumor malignancies.
- Conditions
- Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC
- Trial name
- NCT04383938
- Testing
- APR-246 (eprenetapopt) + Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aprea Therapeutics
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
This phase Ib/II trial studies the side effects and best dose of plinabulin in combination with radiation therapy and immunotherapy in patients with select cancers that have spread to other places in the body (advanced) after…
- Conditions
- Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT04902040
- Testing
- Atezolizumab, Avelumab, Durvalumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy of infigratinib (an oral targeted FGFR1-3 inhibitor) versus placebo, as adjuvant treatment following surgery in adult…
- Trial name
- PROOF302 (NCT04197986)
- Testing
- Infigratinib
- Where
- 143 sites in United States, Belgium and 9 more
- Volunteers
- 39 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Bladder Cancer, Genitourinary Cancer
A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast
The goal of this clinical research study is to evaluate how well ferumoxtran-10, a new Magnetic Resonance Imaging (MRI) contrast agent, can detect cancer in the pelvic lymph nodes or malignant pelvic lymph nodes.
- Conditions
- Bladder Cancer, Genitourinary Cancer, Prostate Cancer
- Trial name
- NCT00147238
- Testing
- Ferumoxtran-10 (USPIO), MR lymphangiography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Urinary Bladder Neoplasms
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
A study comparing nivolumab and bacterial drugs given to help the body's immune system in the bladder versus bacterial drugs alone in high risk bladder cancer participants.
- Trial name
- CheckMate 7G8 (NCT04149574)
- Testing
- nivolumab, Bacillus Calmette-Guérin (BCG)
- Where
- 63 sites in United States, Argentina and 14 more
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer, Transitional Cell Bladder Cancer
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth)…
- Conditions
- Bladder Cancer, Transitional Cell Bladder Cancer, Urethra Cancer, Ureter Cancer
- Trial name
- NCT00661609
- Testing
- AZD4877
- Where
- 36 sites in United States, Canada and 3 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Urothelial Carcinoma
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.
- Trial name
- IMvigor130 (NCT02807636)
- Testing
- Atezolizumab, Carboplatin, Gemcitabine
- Where
- 204 sites in United States, Australia and 33 more
- Volunteers
- 1,213 people
- Sponsor
- Hoffmann-La Roche
Transitional Cell Carcinoma of Bladder, Urethra Cancer
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 in a biochemotherapy regimen either containing cisplatin and gemcitabine or containing gemcitabine alone in patients who…
- Conditions
- Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
- Trial name
- NCT01326871
- Testing
- Cisplatin, Gemcitabine, ALT-801
- Where
- 16 sites in United States
- Volunteers
- 68 people
- Sponsor
- Altor BioScience
Urothelial Carcinoma, Bladder Cancer
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
The purpose of this study is to determine whether sutent (sunitinib)is effective in preventing tumor recurrence in patients with high risk bladder cancer who have previously had chemotherapy and cystectomy (bladder removal).
- Trial name
- NCT01042795
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
This phase I/II trial studies the effect of eribulin mesylate and to see how well it works in treating patients with cancer of the urothelium that has spread to nearby tissue (locally advanced) or to other places in the body…
- Conditions
- Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Urothelial Carcinoma
- Trial name
- NCT00365157
- Testing
- Eribulin Mesylate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 26 sites in United States
- Volunteers
- 168 people
- Sponsor
- National Cancer Institute (NCI)
Low Anterior Resection Syndrome, Malignant Anal Neoplasm
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
This phase II trial studies how well sacral nerve stimulation works in treating low anterior resection syndrome or fecal incontinence (the body's passage of stool without control) in patients with rectal cancer that has spread to…
- Conditions
- Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm
- Trial name
- NCT04066894
- Testing
- Explantation, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Carcinoma, Breast Cancer
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
- Conditions
- Non-Small Cell Lung Carcinoma, Breast Cancer, Melanoma, Upper GI Tract Carcinoma
- Trial name
- NCT00753415
- Testing
- V935, V934-EP
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Bladder Cancer
Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer
A study to compare Hexvix Blue light cstoscopy with standard White light cystoscopy in the detection of bladder cancer.
- Trial name
- NCT05600322
- Testing
- Hexaminolevulinate Hydrochloride, Richard Wolf Photodynamic Diagnostic Equipment (PDD) system
- Where
- 7 sites in China
- Volunteers
- 158 people
- Sponsor
- Photocure
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
This phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment with immune checkpoint inhibitors.
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- IMAGINE (NCT04637594)
- Testing
- Pembrolizumab, Nivolumab, Atezolizumab
- Where
- 377 sites in United States
- Volunteers
- 3 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction.
- Conditions
- Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT04267575
- Testing
- Canady Helios Cold Plasma Scalpel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jerome Canady, M.D.
Urinary Bladder Cancer, Bladder Cancer
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
The purpose of this study is to evaluate the efficacy and tolerability of Vicinium when administered as a monotherapy intravesical instillation in patients with non-invasive urothelial carcinoma in situ (CIS) who failed previous…
- Conditions
- Urinary Bladder Cancer, Bladder Cancer, Bladder Neoplasms, Bladder Tumors
- Trial name
- NCT00462488
- Testing
- Vicinium
- Where
- 21 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Sesen Bio, Inc.
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
This phase II trial studies the side effects of avelumab and how well it works in combination with fluorouracil and mitomycin or cisplatin and radiation therapy in treating participants with muscle-invasive bladder cancer.
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8
- Trial name
- NCT03617913
- Testing
- Avelumab, Cisplatin, Fluorouracil
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Urothelial Carcinoma
Derazantinib and Atezolizumab in Patients With Urothelial Cancer
The purpose of this study was to evaluate efficacy of derazantinib monotherapy or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth factor receptor (FGFR) genetic…
- Trial name
- FIDES-02 (NCT04045613)
- Testing
- Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily+ atezolizumab 1200 mg
- Where
- 66 sites in United States, Australia and 12 more
- Volunteers
- 95 people
- Sponsor
- Basilea Pharmaceutica
Transitional Cell Carcinoma
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
This phase II trial studies how well paclitaxel and pembrolizumab works in treating patients with urothelial cancer that has not responded to previous treatment and has spread to other places in the body.
- Trial name
- NCT02581982
- Testing
- Laboratory Biomarker Analysis, Paclitaxel, Pembrolizumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Wake Forest University Health Sciences